Valneva SE at Jefferies Healthcare Conference Transcript
My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. So it's great pleasure that I'd like to welcome Peter Bühler, the CFO of Valneva. Valneva has a lot going on with their clinical programs, filing for chikungunya and also with the commercial portfolio as well. And so without further ado, I'm going to turn it over to Peter to tell you more about the company. Thanks for joining us, Peter.
Thank you, Maury, and good afternoon, everyone. As usual, we have a forward-looking statement here. I will skip that.
So Valneva, we are a fully integrated specialty vaccine company. And we're basically focusing on prophylactic vaccines. We develop, manufacture, and commercialize those. And we're really focusing on vaccines for infectious diseases with high unmet medical need.
What we're typically targeting is vaccines that are either first in class, best in class, or only in class. So we are highly specialized and targeted in our development. And we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |